MCID: SPN021
MIFTS: 43

Spinal Meningioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Spinal Meningioma

MalaCards integrated aliases for Spinal Meningioma:

Name: Spinal Meningioma 12 20 15 70
Meningioma, Benign, No Icd-O Subtype 70
Spinal Cord Meningioma 12
Meningioma, Spine 20
Meningioma 70

Classifications:



External Ids:

Disease Ontology 12 DOID:1138
MeSH 44 D008579
NCIt 50 C6935
SNOMED-CT 67 189167009
UMLS 70 C0025286 C0347515 C1762616

Summaries for Spinal Meningioma

GARD : 20 Spinal meningioma is a rare type of spinal cord cancer. The spinal cord is part of the central nervous system. This tumor often affects middle-aged women. Tumors of the spinal cord can be either primary or arise from other primary tumors ( metastatic ), and are typically slow growing. The initial signs and symptoms include headache and recent onset of seizures. Other features are motor deficits, sensory deficits, pain, and sphincter dysfunction. The thoracic spine (middle back) is the most common site, followed by the cervical spine (neck). These tumors are rarely seen in the lumbar region (lower back). T he only proven risk factor in the development of meningioma is exposure to ionizing radiation. Also, patients with neurofibromatosis type 2 are at increased risk of developing meningioma. Surgery is the treatment of choice and complete tumor removal is reached in the vast majority of patients. The prognosis after surgical resection is excellent.

MalaCards based summary : Spinal Meningioma, also known as meningioma, benign, no icd-o subtype, is related to secretory meningioma and psammomatous meningioma. An important gene associated with Spinal Meningioma is NF2 (Neurofibromin 2), and among its related pathways/superpathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Thrombin and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and endothelial, and related phenotypes are Increased Nanog expression and Increased Nanog expression

Related Diseases for Spinal Meningioma

Diseases related to Spinal Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 149)
# Related Disease Score Top Affiliating Genes
1 secretory meningioma 31.5 TRAF7 SMARCE1 SMARCB1 NF2
2 psammomatous meningioma 30.8 TRAF7 NF2
3 meningioma, familial 30.6 TRAF7 SMARCE1 SMARCB1 PGR NF2 NF1
4 meningothelial meningioma 30.4 TRAF7 SMARCE1 PGR NF2
5 fibrous meningioma 30.1 TRAF7 NF2
6 neurilemmoma 30.0 SMARCB1 NF2 NF1 LZTR1
7 transitional meningioma 29.8 TRAF7 SMARCE1 PGR NF2
8 benign ependymoma 29.5 NF2 NF1
9 acoustic neuroma 29.5 NF2 NF1 LZTR1
10 spinal canal and spinal cord meningioma 28.2 TRAF7 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4
11 thoracic spinal canal and spinal cord meningioma 11.3
12 lumbar spinal canal and spinal cord meningioma 11.3
13 multiple spinal canal and spinal cord meningioma 11.3
14 cervical spinal canal and spinal cord meningioma 11.3
15 sacral spinal canal and spinal cord meningioma 11.3
16 intracranial meningioma 10.9
17 lymphoplasmacyte-rich meningioma 10.9
18 monosomy 22 10.3 SMARCB1 NF2
19 mn1 c-terminal truncation syndrome 10.3 SMARCE1 NF2
20 intraorbital meningioma 10.3 NF2 LZTR1
21 pediatric meningioma 10.3 TRAF7 NF2
22 lung meningioma 10.3 PGR NF2
23 melanotic neurilemmoma 10.3 SMARCB1 NF2
24 intraventricular meningioma 10.3 TRAF7 NF2
25 meninges hemangiopericytoma 10.3 TRAF7 NF2
26 intraneural perineurioma 10.3 TRAF7 NF2
27 frontal convexity meningioma 10.3 TRAF7 NF2
28 chordoid meningioma 10.3 TRAF7 NF2
29 chordoid glioma 10.3 PGR NF2
30 paraplegia 10.2
31 angiomatous meningioma 10.2 TRAF7 SMARCE1 NF2
32 skull base meningioma 10.2 TRAF7 SMARCE1 NF2
33 schwannomatosis 1 10.2 SMARCB1 NF2 LZTR1
34 sweat gland benign neoplasm 10.2 SMARCB1 PGR
35 rhabdoid meningioma 10.2 TRAF7 SMARCB1 NF2
36 cerebral ventricle cancer 10.2 SMARCB1 NF2
37 cerebrum cancer 10.2 SMARCB1 NF2
38 brain meningioma 10.2 TRAF7 PGR NF2
39 smarca4-deficient sarcoma of thorax 10.2 SMARCB1 SMARCA4
40 supratentorial cancer 10.2 SMARCB1 NF2
41 juvenile type testicular granulosa cell tumor 10.1 SMARCB1 SMARCA4
42 neurofibromatosis 10.1
43 testicular granulosa cell tumor 10.1 SMARCB1 SMARCA4
44 coffin-siris syndrome 3 10.1 SMARCE1 SMARCB1
45 coffin-siris syndrome 4 10.1 SMARCE1 SMARCA4
46 small-cell carcinoma of the ovary of hypercalcemic type 10.1 SMARCA4 DPF1
47 ovarian small cell carcinoma 10.1 SMARCB1 SMARCA4
48 ataxia and polyneuropathy, adult-onset 10.1
49 clear cell adenofibroma 10.1 SMARCA4 PBRM1
50 meningioma, radiation-induced 10.1 TRAF7 SMARCE1 SMARCB1 NF2

Graphical network of the top 20 diseases related to Spinal Meningioma:



Diseases related to Spinal Meningioma

Symptoms & Phenotypes for Spinal Meningioma

GenomeRNAi Phenotypes related to Spinal Meningioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Nanog expression GR00371-A-1 9.43 DPF1 SMARCA4 SMARCB1 SMARCC1 SMARCE1
2 Increased Nanog expression GR00371-A-2 9.43 SMARCE1
3 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

MGI Mouse Phenotypes related to Spinal Meningioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.86 NF1 NF2 PBRM1 PGR SMARCA4 SMARCB1
2 immune system MP:0005387 9.81 ARID1B NF1 NF2 PBRM1 PGR SMARCA4
3 mortality/aging MP:0010768 9.77 ACTL6B ARID1B LZTR1 NF1 NF2 PBRM1
4 muscle MP:0005369 9.1 ARID1B LZTR1 NF1 PGR SMARCA4 SMARCB1

Drugs & Therapeutics for Spinal Meningioma

Drugs for Spinal Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic Acid Approved Phase 4 1197-18-8 5526
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Prilocaine Approved Phase 4 721-50-6 4906
6
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
7 Fibrin Tissue Adhesive Phase 4
8 Neurotransmitter Agents Phase 4
9 Coagulants Phase 4
10 Antifibrinolytic Agents Phase 4
11 Hemostatics Phase 4
12 Anesthetics Phase 4
13 Anesthetics, Local Phase 4
14 Vasoconstrictor Agents Phase 4
15 Adrenergic alpha-Agonists Phase 4
16 Adrenergic beta-Agonists Phase 4
17 Respiratory System Agents Phase 4
18 Anti-Asthmatic Agents Phase 4
19 Epinephryl borate Phase 4
20 Mydriatics Phase 4
21 Sympathomimetics Phase 4
22 Adrenergic Agents Phase 4
23 Adrenergic Agonists Phase 4
24 Bronchodilator Agents Phase 4
25
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
26
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
28
Cisatracurium Approved Phase 3 96946-41-7 62887
29
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
30
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
31
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
32
Aminolevulinic acid Approved Phase 3 106-60-5 137
33 Contraceptives, Postcoital Phase 3
34 Contraceptives, Oral Phase 3
35 Progestins Phase 3
36 Contraceptive Agents Phase 3
37 Antihypertensive Agents Phase 3
38 Photosensitizing Agents Phase 3
39 Dermatologic Agents Phase 3
40
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
41
Hydroxyurea Approved Phase 2 127-07-1 3657
42
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
43
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
44
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
45
Verapamil Approved Phase 2 52-53-9 2520
46
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
47
Mesna Approved, Investigational Phase 2 3375-50-6 598
48
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
49
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
50
carbamide peroxide Approved Phase 2 124-43-6

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study Not yet recruiting NCT04386642 Phase 4 Tranexamic acid;Placebo
5 Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function Evaluated With Diaphragm Thickening Fraction Not yet recruiting NCT04756050 Phase 4 Bupivacaine HCl 0.5% Injectable Solution;Prilocaine HCl % 2 injectable solution;adrenaline amp 0.5mg
6 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
7 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
8 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
9 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Completed NCT03558516 Phase 3 Magnesium group;Normal saline group
10 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
11 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas Recruiting NCT04305470 Phase 3 Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
12 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
13 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
14 Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area Unknown status NCT01849484 Phase 2
15 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
16 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
17 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
18 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
19 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
20 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Completed NCT00006119 Phase 2 hydroxyurea
21 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
22 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
23 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Completed NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
24 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
25 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
26 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
27 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
28 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
29 A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas Completed NCT02831257 Phase 2 AZD2014
30 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
31 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
32 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
33 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
34 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
35 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
36 Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes Completed NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
37 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib
38 A Phase 2 Study of Abemaciclib in Patients With Recurrent Brain Tumors Recruiting NCT03220646 Phase 2 abemaciclib;abemaciclib
39 A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma Recruiting NCT04659811 Phase 2 Pembrolizumab
40 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2
41 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
42 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
43 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg
44 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab
45 A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting NCT04082520 Phase 2 Lutetium Lu 177 Dotatate
46 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
47 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
48 Phase II, Dosimetry Guided, Peptide Receptor Radiotherapy (PRRT) Using 90Y-DOTA tyr3-Octreotide (90Y-DOTATOC) in Children and Adults With Neuroendocrine and Other Somatostatin Receptor Positive Tumors Recruiting NCT03273712 Phase 2 Amino Acids
49 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas Active, not recruiting NCT00895622 Phase 2
50 Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study Active, not recruiting NCT00626730 Phase 2

Search NIH Clinical Center for Spinal Meningioma

Genetic Tests for Spinal Meningioma

Anatomical Context for Spinal Meningioma

MalaCards organs/tissues related to Spinal Meningioma:

40
Spinal Cord, Brain, Endothelial, Pituitary, Breast, Bone, Lymph Node

Publications for Spinal Meningioma

Articles related to Spinal Meningioma:

(show top 50) (show all 285)
# Title Authors PMID Year
1
Demographic and socioeconomic disparities of benign and malignant spinal meningiomas in the United States. 61
33068594 2021
2
The protean manifestations of central nervous system IgG4-related hypertrophic pachymeningitis: a report of two cases. 61
33536053 2021
3
The incidence of venous thromboembolism following surgical resection of intracranial and intraspinal meningioma. A systematic review and retrospective study. 61
33444944 2021
4
Surgical results of the resection of spinal meningioma with the inner layer of dura more than 10 years after surgery. 61
33603112 2021
5
Long-term outcomes of spinal meningioma resection with outer layer of dura preservation technique. 61
33317879 2021
6
Predictive Value of Heterogeneously Enhanced Magnetic Resonance Imaging Findings With Computed Tomography Evidence of Calcification for Severe Motor Deficits in Spinal Meningioma. 61
33285060 2020
7
Necrosis and Brain Invasion Predict Radio-Resistance and Tumor Recurrence in Atypical Meningioma: A Retrospective Cohort Study. 61
32818240 2020
8
A primary meningioma of the lumbar spine with neck metastasis. 61
30624157 2020
9
Spinal meningiomas: Treatment outcome and long-term follow-up. 61
33096449 2020
10
Spinal meningiomas: 61 cases with predictors of early postoperative surgical outcomes. 61
29115099 2020
11
Racial Disparities in the Incidence and Survival of Spinal Meningioma. 61
33708657 2020
12
Triad of meningothelial meningioma, rhabdoid meningioma and ependymoma: successful management of an extremely rare case. 61
32855801 2020
13
Functional outcome after surgical treatment of spinal meningioma. 61
32409209 2020
14
Resection of Spinal Meningioma Using Ultrasonic BoneScalpel Microshaver: Cases, Technique, and Review of the Literature. 61
32726428 2020
15
Low recurrence after Simpson grade II resection of spinal benign meningiomas in a single-institute 10-year retrospective study. 61
32360158 2020
16
Spinal meningiomas: is Simpson grade II resection radical enough? 61
32166387 2020
17
Completely ossified thoracic intradural meningioma in an elderly patient: A case report and literature review. 61
32569229 2020
18
Desmoid fibromatosis following surgical resection of spinal meningioma. 61
32280401 2020
19
Use of Intraoperative CO2 Laser for the Resection of a Ventral Intradural Extramedullary Cervical Spinal Tumor: 2-Dimensional Operative Video. 61
31504883 2020
20
Concurrent intradural meningioma and schwannoma at the same lumbar level in a patient without neurofibromatosis: a case report. 61
29271254 2020
21
Neuro-oncological features of spinal meningiomas: Systematic review. 61
31672597 2020
22
Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy. 61
32954302 2020
23
Spinal meningioma in a patient with multiple sclerosis. 61
32754367 2020
24
Clinical Significance of Pain in Differential Diagnosis between Spinal Meningioma and Schwannoma. 61
32670651 2020
25
The outcome of patients with surgically treated meningioma in England: 1999-2013. A cancer registry data analysis. 61
31526136 2019
26
The epidemiology of spinal schwannoma in the United States between 2006 and 2014. 61
31881538 2019
27
Ossified Spinal Meningioma: A Case Report and a Review of the Literature. 61
31579830 2019
28
Psychosis secondary to recurrent spinal meningioma. 61
31490263 2019
29
Survival in Patients with High-Grade Spinal Meningioma: An Analysis of the National Cancer Database. 61
31203074 2019
30
[Persistent chest pain for 4 months and progressive lower limb weakness for 2 months in a boy]. 61
31416509 2019
31
Trends in the utilization of radiotherapy for spinal meningiomas: insights from the 2004-2015 National Cancer Database. 61
31153154 2019
32
Ossified Metaplastic Spinal Meningioma Without Psammomatous Calcification: A Case Report. 61
31320828 2019
33
Magnetic resonance imaging spectrum of spinal meningioma. 61
30802771 2019
34
[Microscopic keyhole technique for surgical resection of thoracic spinal meningioma via an oblique placing tube]. 61
30955309 2019
35
Microsurgical Resection of Thoracic Meningioma: 2-Dimensional Operative Video. 61
30032268 2019
36
Posterior Cervical Laminoplasty for Resection Intradural Extramedullary Spinal Meningioma: 2-Dimensional Operative Video. 61
30107430 2019
37
Spinal Meningiomas Prognostic Evaluation Score (SPES): predicting the neurological outcomes in spinal meningioma surgery. 61
29516306 2019
38
Treatment outcomes of 17 patients with atypical spinal meningioma, including 4 with metastases: a retrospective observational study. 61
29906618 2019
39
Primary epidural hemangiopericytoma of the thoracic spine: Case report and literature review. 61
30352760 2019
40
Spontaneous Hemorrhage followed by paraparesis in a patient with a Spinal Meningioma. 61
30684702 2019
41
Simpson grade 3 resection does not improve clinical outcome in neglected thoracic psammomatous spinal meningioma? A case report. 61
31362237 2019
42
Clinical and prognostic features of spinal meningioma: a thorough analysis from a single neurosurgical center. 61
30209689 2018
43
Spinal meningioma surgery in the elderly: who benefits? 61
30468359 2018
44
Extradural cervical spinal meningioma mimicking malignancy. 61
30651905 2018
45
Spinal meningioma and factors predictive of post-operative deterioration. 61
29926318 2018
46
Canine spinal meningiomas and nerve sheath tumours in 34 dogs (2008-2016): Distribution and long-term outcome based upon histopathology and treatment modality. 61
29363264 2018
47
Lumbar intraspinal microcystic/reticular schwannoma: Case report and literature review. 61
30278533 2018
48
Spinal Meningioma Arising from the Denticulate Ligament. 61
29729464 2018
49
Arachnoid isolation sign: A predictive imaging feature of spinal meningioma on CT-myelogram. 61
29549812 2018
50
Pigmented intramedullary spinal cord meningioma mimicking a nervous system infection: An unusual report and review of the literature. 61
29766951 2018

Variations for Spinal Meningioma

Expression for Spinal Meningioma

Search GEO for disease gene expression data for Spinal Meningioma.

Pathways for Spinal Meningioma

Pathways related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.51 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PBRM1
2
Show member pathways
13.1 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 DPF1
3
Show member pathways
12.6 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PBRM1
4 12.11 SMARCC2 SMARCC1 SMARCB1 SMARCA4
5
Show member pathways
12.03 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
6
Show member pathways
11.89 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4
7
Show member pathways
11.54 SMARCC2 SMARCC1 SMARCB1 SMARCA4
8 11.52 SMARCC2 SMARCC1 SMARCA4
9
Show member pathways
11.34 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 ARID1B

GO Terms for Spinal Meningioma

Cellular components related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10.13 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
2 nucleus GO:0005634 10.13 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
3 chromatin GO:0000785 9.86 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
4 protein-containing complex GO:0032991 9.85 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4
5 npBAF complex GO:0071564 9.63 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
6 nuclear chromosome GO:0000228 9.58 SMARCE1 SMARCB1 PBRM1
7 SWI/SNF complex GO:0016514 9.5 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 ARID1B
8 XY body GO:0001741 9.43 SMARCC1 SMARCB1
9 brahma complex GO:0035060 9.37 SMARCB1 ARID1B
10 nBAF complex GO:0071565 9.23 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 DPF1

Biological processes related to Spinal Meningioma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.99 SMARCC1 SMARCB1 SMARCA4 PHF10 PGR DPF1
2 regulation of transcription by RNA polymerase II GO:0006357 9.97 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PGR
3 chromatin organization GO:0006325 9.92 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PBRM1
4 positive regulation of transcription, DNA-templated GO:0045893 9.91 SMARCE1 SMARCC2 SMARCC1 SMARCA4 ARID1B ACTL6B
5 nervous system development GO:0007399 9.91 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
6 negative regulation of transcription, DNA-templated GO:0045892 9.89 SMARCE1 SMARCC2 SMARCA4 PHF10 DPF1
7 negative regulation of cell proliferation GO:0008285 9.84 SMARCB1 PBRM1 NF2 NF1
8 spinal cord development GO:0021510 9.56 NF1 ACTL6B
9 chromatin remodeling GO:0006338 9.56 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PBRM1
10 negative regulation of MAPK cascade GO:0043409 9.55 NF2 NF1
11 nucleosome disassembly GO:0006337 9.55 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4
12 positive regulation by host of viral transcription GO:0043923 9.52 SMARCB1 SMARCA4
13 positive regulation of transcription of nucleolar large rRNA by RNA polymerase I GO:1901838 9.48 SMARCB1 SMARCA4
14 RNA polymerase I preinitiation complex assembly GO:0001188 9.46 SMARCB1 SMARCA4
15 positive regulation of glucose mediated signaling pathway GO:1902661 9.4 SMARCB1 SMARCA4
16 ATP-dependent chromatin remodeling GO:0043044 9.23 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PBRM1

Molecular functions related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.65 SMARCE1 SMARCC2 SMARCC1 PBRM1 ACTL6B
2 transcription coregulator activity GO:0003712 9.61 SMARCB1 PHF10 DPF1
3 protein N-terminus binding GO:0047485 9.58 SMARCE1 SMARCC1 SMARCA4
4 histone binding GO:0042393 9.55 SMARCC2 SMARCC1 SMARCA4 PHF10 DPF1
5 transcription coactivator activity GO:0003713 9.5 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 ARID1B
6 lysine-acetylated histone binding GO:0070577 9.46 SMARCA4 PBRM1
7 Tat protein binding GO:0030957 9.37 SMARCB1 SMARCA4
8 RNA polymerase I CORE element sequence-specific DNA binding GO:0001164 9.32 SMARCB1 SMARCA4
9 nucleosomal DNA binding GO:0031492 9.02 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4

Sources for Spinal Meningioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....